Anna D Wagner1, Axel Grothey2, Thierry Andre3, Jesse G Dixon4, Norman Wolmark5, Daniel G Haller6, Carmen J Allegra7, Aimery de Gramont8, Eric VanCutsem9, Steven R Alberts10, Thomas J George11, Michael J O'Connell12, Christopher Twelves13, Julien Taieb14, Leonard B Saltz15, Charles D Blanke16, Edoardo Francini17, Rachel Kerr18, Greg Yothers19, Jean F Seitz20, Silvia Marsoni21, Richard M Goldberg22, Qian Shi4. 1. Division of Medical Oncology, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 2. West Cancer Center and Research Institute, Germantown, TN, USA. 3. Sorbonne University and Saint-Antoine Hospital, Paris, France. 4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 5. NRG Oncology and the University of Pittsburgh , Pittsburgh, PA, USA. 6. Abramson Cancer Center, Philadelphia, PA, USA. 7. The University of Florida, Gainesville, FL, USA. 8. Franco-British Institute, Levallois-Perret, France. 9. University of Leuven, Leuven, Belgium. 10. Department of Oncology, Mayo Clinic, Rochester, MN, USA. 11. Department of Medicine and University of Florida Health Cancer Center, Gainesville, FL, USA. 12. NSABP Foundation, Pittsburgh, PA, USA. 13. Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK. 14. Department of Gastroenterology, Georges-Pompidou European Hospital, AP-HP, Sorbonne Paris Cité, Université de Paris, Paris, France. 15. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 16. Southwest Oncology Group, Ann Arbor, MI, USA. 17. University of Florence, Florence, Italy. 18. Adjuvant Colorectal Cancer Group, University of Oxford, Oxford, UK. 19. NRG Oncology and the University of Pittsburgh, Pittsburgh, PA, USA. 20. Timone Hospital, Aix-Marseille-University, Marseille, France. 21. Precision Oncology, The FIRC Institute Of Molecular Oncology, Milan, Italy. 22. West Virginia University Cancer Institute, Morgantown, WV, USA.
Abstract
BACKGROUND: Adjuvant chemotherapy is a standard treatment option for patients with stage III and high-risk stage II colon cancer. Sex is one of several factors responsible for the wide inter-patient variability in drug responses. Amalgamated data on the effect of sex on the toxicity of current standard adjuvant treatment for colorectal cancer are missing. METHODS: The objective of our study was to compare incidence and severity of major toxicities of fluoropyrimidine- (5FU or capecitabine) based adjuvant chemotherapy, with or without oxaliplatin, between male and female patients after curative surgery for colon cancer. Adult patients enrolled in 27 relevant randomized trials included in the ACCENT (Adjuvant Colon Cancer End Points) database, a large, multi-group, international data repository containing individual patient data, were included. Comparisons were conducted using logistic regression models (stratified by study and treatment arm) within each type of adjuvant chemotherapy (5FU, FOLFOX, capecitabine, CAPOX, and FOLFIRI). The following major toxicities were compared (grade III or IV and grade I-IV, according to National Cancer Institute Common Terminology Criteria [NCI-CTC] criteria, regardless of attribution): nausea, vomiting, nausea or vomiting, stomatitis, diarrhea, leukopenia, neutropenia, thrombocytopenia, anemia, and neuropathy (in patients treated with oxaliplatin). RESULTS: Data from 34 640 patients were analyzed. Statistically significant and clinically relevant differences in the occurrence of grade III or IV nonhematological {especially nausea (5FU: odds ratio [OR] = 2.33, 95% confidence interval [CI] = 1.90 to 2.87, P < .001; FOLFOX: OR = 2.34, 95% CI = 1.76 to 3.11, P < .001), vomiting (5FU: OR = 2.38, 95% CI = 1.86 to 3.04, P < .001; FOLFOX: OR = 2.00, 95% CI = 1.50 to 2.66, P < .001; CAPOX: OR = 2.32, 95% CI = 1.55 to 3.46, P < .001), and diarrhea (5FU: OR = 1.35, 95% CI = 1.21 to 1.51, P < .001; FOLFOX: OR = 1.60, 95% CI = 1.35 to 1.90, P < .001; FOLFIRI: OR = 1.57, 95% CI = 1.25 to 1.97, P < .001)} as well as hematological toxicities (neutropenia [5FU: OR = 1.55, 95% CI = 1.37 to 1.76, P < .001; FOLFOX: OR = 1.96, 95% CI = 1.71 to 2.25, P < .001; FOLFIRI: OR = 2.01, 95% CI = 1.66 to 2.43, P < .001; capecitabine: OR = 4.07, 95% CI = 1.84 to 8.99, P < .001] and leukopenia [5FU: OR = 1.74, 95% CI = 1.40 to 2.17, P < .001; FOLFIRI: OR = 1.75, 95% CI = 1.28 to 2.40, P < .001]) were observed, with women being consistently at increased risk. CONCLUSIONS: Our analysis confirms that women with colon cancer receiving adjuvant fluoropyrimidine-based chemotherapy are at increased risk of toxicity. Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation.
BACKGROUND: Adjuvant chemotherapy is a standard treatment option for patients with stage III and high-risk stage II colon cancer. Sex is one of several factors responsible for the wide inter-patient variability in drug responses. Amalgamated data on the effect of sex on the toxicity of current standard adjuvant treatment for colorectal cancer are missing. METHODS: The objective of our study was to compare incidence and severity of major toxicities of fluoropyrimidine- (5FU or capecitabine) based adjuvant chemotherapy, with or without oxaliplatin, between male and female patients after curative surgery for colon cancer. Adult patients enrolled in 27 relevant randomized trials included in the ACCENT (Adjuvant Colon Cancer End Points) database, a large, multi-group, international data repository containing individual patient data, were included. Comparisons were conducted using logistic regression models (stratified by study and treatment arm) within each type of adjuvant chemotherapy (5FU, FOLFOX, capecitabine, CAPOX, and FOLFIRI). The following major toxicities were compared (grade III or IV and grade I-IV, according to National Cancer Institute Common Terminology Criteria [NCI-CTC] criteria, regardless of attribution): nausea, vomiting, nausea or vomiting, stomatitis, diarrhea, leukopenia, neutropenia, thrombocytopenia, anemia, and neuropathy (in patients treated with oxaliplatin). RESULTS: Data from 34 640 patients were analyzed. Statistically significant and clinically relevant differences in the occurrence of grade III or IV nonhematological {especially nausea (5FU: odds ratio [OR] = 2.33, 95% confidence interval [CI] = 1.90 to 2.87, P < .001; FOLFOX: OR = 2.34, 95% CI = 1.76 to 3.11, P < .001), vomiting (5FU: OR = 2.38, 95% CI = 1.86 to 3.04, P < .001; FOLFOX: OR = 2.00, 95% CI = 1.50 to 2.66, P < .001; CAPOX: OR = 2.32, 95% CI = 1.55 to 3.46, P < .001), and diarrhea (5FU: OR = 1.35, 95% CI = 1.21 to 1.51, P < .001; FOLFOX: OR = 1.60, 95% CI = 1.35 to 1.90, P < .001; FOLFIRI: OR = 1.57, 95% CI = 1.25 to 1.97, P < .001)} as well as hematological toxicities (neutropenia [5FU: OR = 1.55, 95% CI = 1.37 to 1.76, P < .001; FOLFOX: OR = 1.96, 95% CI = 1.71 to 2.25, P < .001; FOLFIRI: OR = 2.01, 95% CI = 1.66 to 2.43, P < .001; capecitabine: OR = 4.07, 95% CI = 1.84 to 8.99, P < .001] and leukopenia [5FU: OR = 1.74, 95% CI = 1.40 to 2.17, P < .001; FOLFIRI: OR = 1.75, 95% CI = 1.28 to 2.40, P < .001]) were observed, with women being consistently at increased risk. CONCLUSIONS: Our analysis confirms that women with colon cancer receiving adjuvant fluoropyrimidine-based chemotherapy are at increased risk of toxicity. Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation.
Authors: Sari L Reisner; Tonia Poteat; JoAnne Keatley; Mauro Cabral; Tampose Mothopeng; Emilia Dunham; Claire E Holland; Ryan Max; Stefan D Baral Journal: Lancet Date: 2016-06-17 Impact factor: 79.321
Authors: Adam M Lee; Qian Shi; Emily Pavey; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Richard M Goldberg; Robert B Diasio Journal: J Natl Cancer Inst Date: 2014-11-07 Impact factor: 13.506
Authors: Pasquale F Innominato; Sylvie Giacchetti; Thierry Moreau; Rune Smaaland; Christian Focan; Georg A Bjarnason; Carlo Garufi; Stefano Iacobelli; Marco Tampellini; Salvatore Tumolo; Carlos Carvalho; Abdoulaye Karaboué; Francis Lévi Journal: Chronobiol Int Date: 2011-08 Impact factor: 2.877
Authors: Matthias Schwab; Ulrich M Zanger; Claudia Marx; Elke Schaeffeler; Kathrin Klein; Jürgen Dippon; Reinhold Kerb; Julia Blievernicht; Joachim Fischer; Ute Hofmann; Carsten Bokemeyer; Michel Eichelbaum Journal: J Clin Oncol Date: 2008-02-25 Impact factor: 44.544
Authors: F Mueller; B Büchel; D Köberle; S Schürch; B Pfister; St Krähenbühl; T K Froehlich; C R Largiader; M Joerger Journal: Cancer Chemother Pharmacol Date: 2012-11-09 Impact factor: 3.333
Authors: Sâmia Sousa Duarte; Daiana Karla Frade Silva; Thaís Mangeon Honorato Lisboa; Rawny Galdino Gouveia; Camyla Caroliny Neves de Andrade; Valgrícia Matias de Sousa; Rafael Carlos Ferreira; Ricardo Olimpio de Moura; Joilly Nilce Santana Gomes; Patricia Mirella da Silva; Fátima de Lourdes Assunção Araújo de Azevedo; Tatjana S L Keesen; Juan Carlos Ramos Gonçalves; Leônia Maria Batista; Marianna Vieira Sobral Journal: Pharmacol Rep Date: 2022-03-17 Impact factor: 3.024
Authors: Asha Mathew; Amit Jiwan Tirkey; Hongjin Li; Alana Steffen; Mark B Lockwood; Crystal L Patil; Ardith Z Doorenbos Journal: Semin Oncol Nurs Date: 2021-09-03 Impact factor: 3.527
Authors: Matt S Zinter; A Birgitta Versluys; Caroline A Lindemans; Madeline Y Mayday; Gustavo Reyes; Sara Sunshine; Marilynn Chan; Elizabeth K Fiorino; Maria Cancio; Sabine Prevaes; Marina Sirota; Michael A Matthay; Sandhya Kharbanda; Christopher C Dvorak; Jaap J Boelens; Joseph L DeRisi Journal: Sci Transl Med Date: 2022-03-09 Impact factor: 19.319
Authors: Neil S Zheng; Fei Wang; Rajiv Agarwal; Robert J Carroll; Wei-Qi Wei; Jordan Berlin; Xiao-Ou Shu Journal: Cancer Med Date: 2021-09-21 Impact factor: 4.452
Authors: P García-Alfonso; M Saiz-Rodríguez; R Mondéjar; J Salazar; D Páez; A M Borobia; M J Safont; I García-García; R Colomer; X García-González; M J Herrero; L A López-Fernández; F Abad-Santos Journal: Clin Transl Oncol Date: 2021-11-13 Impact factor: 3.405
Authors: Shehara Mendis; Seerat Anand; Joanna M Karasinska; Arvind Dasari; Joseph M Unger; Anirudh Gothwal; Lee M Ellis; Gauri Varadhachary; Scott Kopetz; Michael J Overman; Kanwal Raghav; Jonathan M Loree Journal: Oncologist Date: 2020-10-07 Impact factor: 5.837